Sonida Senior Living Valuation

Is SNDA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SNDA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SNDA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SNDA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SNDA?

Key metric: As SNDA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SNDA. This is calculated by dividing SNDA's market cap by their current revenue.
What is SNDA's PS Ratio?
PS Ratio	1.7x
Sales	US$253.20m
Market Cap	US$408.59m

SNDA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.1x
Enterprise Value/EBITDA	37.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does SNDA's PS Ratio compare to its peers?

The above table shows the PS ratio for SNDA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.6x
CYH Community Health Systems	0.04x	2.0%	US$504.4m
AUNA Auna	0.5x	10.6%	US$535.9m
BKD Brookdale Senior Living	0.4x	5.6%	US$1.0b
JYNT Joint	1.4x	-13.8%	US$164.1m
SNDA Sonida Senior Living	1.7x	n/a	US$408.6m

Price-To-Sales vs Peers: SNDA is expensive based on its Price-To-Sales Ratio (1.7x) compared to the peer average (0.6x).

Price to Sales Ratio vs Industry

How does SNDA's PS Ratio compare vs other companies in the US Healthcare Industry?

31 Companies	Price / Sales	Estimated Growth	Market Cap
MCK McKesson	0.2x	8.1%	US$78.15b
CVS CVS Health	0.2x	4.6%	US$70.18b
COR Cencora	0.2x	6.4%	US$47.23b
CNC Centene	0.2x	5.5%	US$29.19b

31 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: SNDA is expensive based on its Price-To-Sales Ratio (1.7x) compared to the US Healthcare industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is SNDA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SNDA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SNDA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Lantheus Holdings

US$5.5b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$79.43

-0.4%

16.3%

Centene

US$29.2b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$57.81

-0.4%

-22.1%

Patterson Companies

US$1.8b

Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.

PDCO

US$20.41

2.1%

-36.8%